Last reviewed · How we verify
ETN Alone
ETN (etanercept) is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
ETN (etanercept) is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | ETN Alone |
|---|---|
| Also known as | etanercept |
| Sponsor | Japan Biological Agent Study Integrated Consortium |
| Drug class | TNF-α inhibitor (TNF receptor fusion protein) |
| Target | TNF-α (tumor necrosis factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
ETN acts as a soluble TNF receptor that competitively inhibits TNF-α from engaging membrane-bound TNF receptors on immune and inflammatory cells. By sequestering TNF-α, it suppresses the inflammatory cascade and reduces production of downstream inflammatory mediators, thereby dampening pathological immune responses in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Plaque psoriasis
- Juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Serious infections (including tuberculosis)
- Demyelinating disease
- Congestive heart failure exacerbation
Key clinical trials
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- Effect of Thumbtack Needle (TN) on Ovarian Reserve Function of Women With Diminished Ovarian Reserve (DOR) (NA)
- Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis (PHASE3)
- A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis
- Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis (NA)
- Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC (PHASE1)
- A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders (PHASE1)
- Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |